vs
DILLARD'S, INC.（DDS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
DILLARD'S, INC.的季度营收约是Revvity的1.9倍（$1.5B vs $772.1M），Revvity净利率更高（12.7% vs 8.8%，领先3.9%），Revvity同比增速更快（5.9% vs 2.9%），Revvity自由现金流更多（$161.8M vs $156.2M），过去两年Revvity的营收复合增速更高（9.0% vs -16.9%）
Dillard's, Inc.是美国知名连锁百货企业，1938年由威廉·T·迪拉德创立，总部位于阿肯色州小石城，目前在全美30个州运营约272家门店，其中得克萨斯州、佛罗里达州分别设有57家、42家门店，为其门店数量最多的两个区域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DDS vs RVTY — 直观对比
营收规模更大
DDS
是对方的1.9倍
$772.1M
营收增速更快
RVTY
高出2.9%
2.9%
净利率更高
RVTY
高出3.9%
8.8%
自由现金流更多
RVTY
多$5.6M
$156.2M
两年增速更快
RVTY
近两年复合增速
-16.9%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $129.8M | $98.4M |
| 毛利率 | 43.4% | — |
| 营业利润率 | 11.5% | 14.5% |
| 净利率 | 8.8% | 12.7% |
| 营收同比 | 2.9% | 5.9% |
| 净利润同比 | 4.2% | 3.9% |
| 每股收益（稀释后） | $8.31 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DDSRVTY
| Q4 25 | $1.5B | $772.1M | ||
| Q3 25 | $1.5B | $698.9M | ||
| Q2 25 | $1.5B | $720.3M | ||
| Q1 25 | $2.0B | $664.8M | ||
| Q4 24 | $1.4B | $729.4M | ||
| Q3 24 | $1.5B | $684.0M | ||
| Q2 24 | $1.5B | $691.7M | ||
| Q1 24 | $2.1B | $649.9M |
净利润DDSRVTY
| Q4 25 | $129.8M | $98.4M | ||
| Q3 25 | $72.8M | $46.7M | ||
| Q2 25 | $163.8M | $53.9M | ||
| Q1 25 | $214.4M | $42.2M | ||
| Q4 24 | $124.6M | $94.6M | ||
| Q3 24 | $74.5M | $94.4M | ||
| Q2 24 | $180.0M | $55.4M | ||
| Q1 24 | $250.5M | $26.0M |
毛利率DDSRVTY
| Q4 25 | 43.4% | — | ||
| Q3 25 | 36.6% | 53.6% | ||
| Q2 25 | 43.9% | 54.5% | ||
| Q1 25 | 34.9% | 56.5% | ||
| Q4 24 | 42.6% | — | ||
| Q3 24 | 37.6% | 56.3% | ||
| Q2 24 | 44.6% | 55.7% | ||
| Q1 24 | 36.6% | 54.6% |
营业利润率DDSRVTY
| Q4 25 | 11.5% | 14.5% | ||
| Q3 25 | 6.2% | 11.7% | ||
| Q2 25 | 14.0% | 12.6% | ||
| Q1 25 | 11.7% | 10.9% | ||
| Q4 24 | 11.4% | 16.3% | ||
| Q3 24 | 6.5% | 14.3% | ||
| Q2 24 | 15.2% | 12.4% | ||
| Q1 24 | 13.3% | 6.8% |
净利率DDSRVTY
| Q4 25 | 8.8% | 12.7% | ||
| Q3 25 | 4.8% | 6.7% | ||
| Q2 25 | 10.7% | 7.5% | ||
| Q1 25 | 10.6% | 6.4% | ||
| Q4 24 | 8.7% | 13.0% | ||
| Q3 24 | 5.0% | 13.8% | ||
| Q2 24 | 11.6% | 8.0% | ||
| Q1 24 | 11.8% | 4.0% |
每股收益（稀释后）DDSRVTY
| Q4 25 | $8.31 | $0.86 | ||
| Q3 25 | $4.66 | $0.40 | ||
| Q2 25 | $10.39 | $0.46 | ||
| Q1 25 | $13.41 | $0.35 | ||
| Q4 24 | $7.73 | $0.77 | ||
| Q3 24 | $4.59 | $0.77 | ||
| Q2 24 | $11.09 | $0.45 | ||
| Q1 24 | $15.41 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.0B | $7.3B |
| 总资产 | $4.3B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DDSRVTY
| Q4 25 | $1.1B | $919.9M | ||
| Q3 25 | $1.0B | $931.4M | ||
| Q2 25 | $900.5M | $991.8M | ||
| Q1 25 | $717.9M | $1.1B | ||
| Q4 24 | $980.4M | $1.2B | ||
| Q3 24 | $946.7M | $1.2B | ||
| Q2 24 | $817.8M | $2.0B | ||
| Q1 24 | $808.3M | $1.7B |
股东权益DDSRVTY
| Q4 25 | $2.0B | $7.3B | ||
| Q3 25 | $1.9B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $2.0B | $7.7B | ||
| Q3 24 | $1.9B | $7.9B | ||
| Q2 24 | $1.9B | $7.9B | ||
| Q1 24 | $1.7B | $7.8B |
总资产DDSRVTY
| Q4 25 | $4.3B | $12.2B | ||
| Q3 25 | $3.7B | $12.1B | ||
| Q2 25 | $3.9B | $12.4B | ||
| Q1 25 | $3.5B | $12.4B | ||
| Q4 24 | $4.1B | $12.4B | ||
| Q3 24 | $3.7B | $12.8B | ||
| Q2 24 | $3.9B | $13.4B | ||
| Q1 24 | $3.4B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $186.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $156.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 10.6% | 21.0% |
| 资本支出强度资本支出/营收 | 2.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.44× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $781.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流DDSRVTY
| Q4 25 | $186.5M | $182.0M | ||
| Q3 25 | $86.8M | $138.5M | ||
| Q2 25 | $232.6M | $134.3M | ||
| Q1 25 | $364.7M | $128.2M | ||
| Q4 24 | $173.5M | $174.2M | ||
| Q3 24 | $-68.4M | $147.9M | ||
| Q2 24 | $244.4M | $158.6M | ||
| Q1 24 | $436.5M | $147.6M |
自由现金流DDSRVTY
| Q4 25 | $156.2M | $161.8M | ||
| Q3 25 | $60.1M | $120.0M | ||
| Q2 25 | $215.8M | $115.5M | ||
| Q1 25 | $349.3M | $112.2M | ||
| Q4 24 | $145.4M | $149.8M | ||
| Q3 24 | $-94.3M | $125.6M | ||
| Q2 24 | $209.2M | $136.6M | ||
| Q1 24 | $408.2M | $129.7M |
自由现金流率DDSRVTY
| Q4 25 | 10.6% | 21.0% | ||
| Q3 25 | 4.0% | 17.2% | ||
| Q2 25 | 14.1% | 16.0% | ||
| Q1 25 | 17.3% | 16.9% | ||
| Q4 24 | 10.2% | 20.5% | ||
| Q3 24 | -6.3% | 18.4% | ||
| Q2 24 | 13.5% | 19.7% | ||
| Q1 24 | 19.2% | 20.0% |
资本支出强度DDSRVTY
| Q4 25 | 2.1% | 2.6% | ||
| Q3 25 | 1.8% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 0.8% | 2.4% | ||
| Q4 24 | 2.0% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 2.3% | 3.2% | ||
| Q1 24 | 1.3% | 2.7% |
现金转化率DDSRVTY
| Q4 25 | 1.44× | 1.85× | ||
| Q3 25 | 1.19× | 2.97× | ||
| Q2 25 | 1.42× | 2.49× | ||
| Q1 25 | 1.70× | 3.03× | ||
| Q4 24 | 1.39× | 1.84× | ||
| Q3 24 | -0.92× | 1.57× | ||
| Q2 24 | 1.36× | 2.87× | ||
| Q1 24 | 1.74× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DDS
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
